thank and everyone, joining first Hello, for call. Dyadic’s XXXX quarter you conference
to are great a off start XXXX. in We
and internationally government industry, speed praise recognition its U.S. efficiencies continues agencies. and in and garner technology the academia, to and CX Our from for
year-over-year QX. collaborations of We are and growth strong revenue delivering for XX.X% research new multiple
of technological recent will core we today's our highlight development I each markets. to continue the and successes On achieve advances across Joe and significant have and business call,
in this with continuing additional while revenues Janssen, We future bringing about for like partnerships the working and Phibro/Abic, collaborations and Rubic others, are long-term commercialization while growth and week current with our Fermbox ongoing announced on co-development the marketing earlier Bio. prospects excited our and and collaborations agreement
demand for core across our continues exponentially. global The proteins to enzymes grow and verticals
protein Our differentiating for markets, versatility, robustness cost overcome challenges, platforms production gene speed Dapibus higher CX scale each and development, of and expression of helping as productivity, manufacturing and microbial benefits commercial such flexible others. among lower these offer
and We believe develop our CX enzymes we value and are verticals precipice proteins will shareholder increase Dyadic would applying Dapibus that across and or the lead to of for at near that monetization our significantly collaborators. to
lines protein what In platform makes our unique production highlighted drugs. biologic fungal versus to filamentous the vaccines traditional currently full-year call, used XXXX CX I manufacture cell that and are
or XXXx fermentation productive two be or than removed also in In weeks baculovirus is and cells, has used more hamster produce a ovary which viruses both processing need human time addition, are downstream Chinese and up cells. CX to and no being CX animal baculovirus-insect vaccines like health to shorter that in more to
being with for platform CX protein CX recombinant amounts lower aspect used than of and production. cell today. achievements these recombinant that greater the vaccines protein study led produce The currently development in the characteristics more awareness from CX produced at interest in can increased first-in-human a has our to key production of data lines vaccine and is cost and coupled antigen, These rapidly scientific
workshop of and company FDA for and message recombinant This only one platform has COVID-XX at the companies to to FDA, BARDA invited vaccines. BARDA Dyadic six being April led the next-generation XX, the resonated led and protein-based with technology present
addition effective Our for highlighting pandemic response. and recombinant to this and vaccines rapid, inclusion growing production develop the protein platform and to need for workshop efficient CX pharmaceutical in validates manufacture our preparedness and platforms in the interest
SK and major next generation alongside presented Sanofi, through and have of the recombinant Novavax against to enhance pandemic coronavirus and broader protein COVID-XX Bio vaccines more potential protection COVID concern. At the I that combat have role workshop, variants current can FDA durable coverage companies to efforts vaccines pharmaceutical that the as the such for
In protein the is status for I The recombinant regulatory from vaccine provided of agencies of booster produced press that record our RBD establish on candidate. will trial proteins an to a this we the release, update for from with Phase Joe production more today's provide platform. COVID-XX protein a first-in-human safety CX data DYAI-XXX, trial later. helping
to virus, traction scientists infectious Ebola Zika applications EU virus, the multiple as of the Marburg as of Nile candidates. grant as the for receiving disease West Sudan continuing vaccine through the variety second candidates generation expand COVID-XX CX such and platform Rift Valley well virus, wide with in are and the We submitted U.S. in collaboration virus Fever
While when critical utilize platform we potential evaluation addition efficiently, cell that antigens line the previously of criterion for provides that for have targets. the data capable unparalleled partners is rapidly CX choosing for producing their demonstrated protein produced commercialization CX vaccine complex data of quantities a first-in-human of
those superior imperative cell the is expressed to are CX by It lines proteins in other to and terms equal produced or of quality.
similarity number a and ovary by hamster produced mAbs. third-party were CX monoclonal of mAbs, antibodies, multiple which third or neutralizing produced that binding parties mAbs assays demonstrated reported assayed activity CHO expressed have and between the Chinese great who We
and to select cell have targets quality regulatory required products a comparator to non-human for these the CX profile is critical lines to as completed commercial this COVID-XX antibody showing partners monoclonal primate signs potential our for CHO-produced standards comparability development. the study, produce safety and of their a mediated monoclonal antibody of One ensure Again, the they enhancement. for clinical with produced antibodies no
biomolecules. designing ferritin express complex and better lines such We conjugating as been antigens on developed to proteins, focusing We've CX also have nanoparticles. cell
influenza an COVID-XX, antigen and Additionally, targeting trimerization we durability. increase AMHCX to that developed domain vaccine as the antigens several with system for included well as a and efficacy
with are evaluated better partners CX-produced Virovax, release, areas today's such antigens and adjuvants and disease these may seen as COVID-XX influenza or relevant pandemic when have may like also in biomolecules In our you are with we and seasonal being new seen, and testing have not animal These longer-lasting have in to of advancements range rapidly improved wide as across trials. enable such more and effective be more the vaccines a and flu more HXNX bird other as Dyadic affordably. its develop infectious quantities larger or could diseases manufactured commonly partners in potential that known
companies Epygen At Hengrui, Rubic as continent vaccine our development of products we Health India. term for clinical Chinese leading our our DYAI-XXX focus vaccine Pharmaceuticals commercial longer and in African pharmaceutical the continue partnerships as well largest the candidate, advancing one with partners bivalent building COVID-XX with same with time, Janssen with and sustaining pharmaceutical on collaboration One the and COVID-XX like strategic a and of
for interested are Discussions additional several using with parties developed ongoing the and and countries. developing applying potential CX of in
with positions of US$X.XX as these with QX of We Alphazyme what fees provides to obtain done continue we The generate our the have in our similar XXXX to from generated case later to us million and equity an in using equity BDI Alphazyme. smaller upfront stakes access cash can't in and This a two to to expect sale cash. of with was companies technology who pay BDI equity total afford in opportunity the XXXX. sale
objectives, of and Additionally, products on commercialization we shorter-term associated royalty payments cost to we've a Alphazyme. opportunities have time, sales that Also milestone based product development. by on the potential include CX-expressed receive and less human have refined XXXX, in focus to risk health our with
at are expressed these in example our high today, this is been serum An sample release have levels which towards as of our shared shift we've We albumin to beginning commercializing the strategy and begun opportunities. customers. projects, recombinant potential we
a as $X.X treatment is for common Pharmaceutical due deployed a development many multitude segment, In growing being R&D. diagnostic vaccines over a and is only points and are serum these market in to increased The There tool a X% approximately animal disease, global different but of price at billion reagent albumin use is grades currently the albumin albumin serum human market, in in of the of as markets. potential health. markets of used not across product and year
high pricing potential Dapibus CX low-cost due Dyadic to to our using has albumin serum platforms at media. produce and animal-free competitive productivity the microbial
the commercialization for additional for application cell alternative albumin segment in Dyadic Another product verticals. culture opportunity media, our with protein serum across near-term is providing
high near-term opportunity and vein, protein CYPXXX the use enzymes enzyme. similar uses. corporate enzymes that drug, another issued fungal greatest showed we vaccines potentially publication of production where filamentous the active the a the other enhance part development the adheres required as an or a strategy and to diagnostics XXXX, poster chiral being of enzymes. is us have $XX synthesis a therapeutic, industry, biologics CYPXXX in targets identify first market can produce are challenge diagnostic, and other CX billion for in our cell the major Achieving enzyme are enzyme In yields research a for specifically a product line and protein to of example global impact. potential to to This enzymes of small molecule pharmaceutical for and our that of a technology
human to our opportunities. programs potential decreases whose timeline our and of have enzymes pipeline revenue This internal core is an or to capability across lengthy are and development improving on trials. not our clinical commercial utilization commercialization We proteins verticals with dependent potential
addition IP with are our estate. clinical robust generated, we technology the to In a data being protecting
with antigens the ongoing of allowance CX a allowance year, such Office Patent month application for half animal a bird that company's Dyadic the and U.S. we trials I'm timely producing that flu claims protein other development trials This additional announced notice cover platform. are HXNX infectious for with of from as say this patent Trademark scheduled comes diseases. and pandemic out and development production allows and year and seasonal at earlier manufacture influenza than pleased carried the of last whose are dozen to Dyadic received influenza more CX and from and as forefront vaccine the vaccines patent animal is the last or being
currently flu The billion with multivalent There's vaccines are verticals over efforts not translating expected a the recognition more health, to they're advancement is available effective approximately interest scientific in been our human for have that at XXXX as unmet and more and to but influenza market we human data health. into US$X vaccines. by animal billion leading need grow such only global the accelerated in other It's and generating $XX market. core increased valued reported
between verticals. markets we have in global impact an health and an health significant and health. sensitivity for What the that our similarities this science market vaccines and supply the the outbreak potentially can Dyadic human and across animal these needs makes many margin are There for proteins, leveraging chain the attractive and the segment are on therapeutic animal is human of core
we well. This on example serves not to The has be in immense just that other disease chain rapidly such one at supply antigen. production level a animal potential grams and why CX of production an very ongoing health. response human, of last stockpiling. into as cost for solution a for a and record produce believe can is and avian antigen poultry we but infectious year, had outbreak impacts pandemic per achieved as global can flu Late global impact also antigens platform we markets ripple response or CX livestock quantities of liter making preparedness large a the announced the XX and low pandemic We platform
proteins Dyadic near-term or Our this pursuits animal capability and in which not Ingredients a opportunity promise our our verticals excitement segment potential requirements. great significant fully agreement does terms The resource we joint of with alternative require development holds also our departure health of third funded of Exploiting collaborator. is one alternative terms technical an and of from Food vertical Global by protein and anchored in revenue. area believe for human
from in the achievement joint this payment have first scientific our this development quarter project. on the received We data based milestone our agreement of
Dyadic health Dyadic the rapidly biological and low-cost and non-pharmaceutical support proteins, designed a projects as existing resources Dapibus microbial use further platform, to future development products expression this such enable is to market. in and metabolites of dedicate manufacture its wellness. large-scale other has food, is enzymes, launched customized applications for within and and filamentous production and which fungal-based nutrition, the protein continuing and for growing platform, gene rapid
our I'll core Joe? Phase Business Officer, now over development our to to trial efforts turn Joe provide our the a progress business Hazelton, across call and more update on verticals. to I discuss Chief detailed
